Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 | P01008 | 3/20 | 0.85 |
| ▸ | FGF1 | P05230 | 4/20 | 0.57 |
| ▸ | F10 | P00742 | 6/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.48 |
| ▸ | BDNF | P23560 | 2/20 | 0.41 |
| ▸ | PTN | P21246 | 1/20 | 0.41 |
| ▸ | MDK | P21741 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idraparinux SCHEMBL427808 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| Idraparinux SCHEMBL29382311 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12458587 | 0.93 | SERPINC1 (0.75) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12729453 | 0.92 | SERPINC1 (0.74) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL15896273 | 0.88 | SERPINC1 (0.69) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12799309 | 0.87 | SERPINC1 (0.68) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL17660081 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL13551204 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL4732494 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL29890443 | 0.85 | SERPINC1 (0.65) | SERPINC1FGF1F10F2FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080097-A | Fucosylated heparin pentasaccharide and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| CN-119823200-A | Preparation method of fondaparinux sodium heparin pentasaccharide and method for synthesizing fondaparinux sodium heparin pentasaccharide by taking naphthylmethyl as temporary protecting group | 海南大学 | 2025-04-15 | — | — | CN | claimed |
| WO-2025054300-A1 | POLYMERIC VENOUS VALVE SYSTEMS AND METHODS OF MAKING AND USING THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-03-13 | — | — | WO | claimed |
| CN-117777320-A | Low molecular weight heparin mimics based on heparin pentasaccharide and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-03-29 | — | — | CN | claimed |
| CN-117777216-A | Preparation method and application of neutralizable biotinylation heparin pentasaccharide | 中国科学院上海药物研究所 | 2024-03-29 | — | — | CN | claimed |
| WO-2024061270-A1 | HEPARIN PENTASACCHARIDE-BASED LOW MOLECULAR WEIGHT HEPARIN MIMETIC, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2024-03-28 | — | — | WO | claimed |
| WO-2024061271-A1 | PREPARATION METHOD FOR BIOTINYLATED HEPARIN PENTASACCHARIDE CAPABLE OF BEING NEUTRALIZED AND USE | 中国科学院上海药物研究所 | 2024-03-28 | — | — | WO | claimed |
| CN-117683830-A | Anticoagulant heparin-chondroitin chimeric sugar molecule and preparation method and application thereof | 山东大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2024032575-A1 | HEPARIN DODECASACCHARIDE CONTAINING DOUBLE ANTITHROMBIN BINDING SEQUENCE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 山东大学 | 2024-02-15 | — | — | WO | claimed |
| CN-114957354-B | Heparin pentasaccharide structure compound | 南开大学 | 2023-11-24 | — | — | CN | claimed |
| CN-113583151-B | Heparin molecules containing AT binding sequences and continuous 2-O-glucuronic acid residues, and preparation method and application thereof | 山东大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115417937-B | Heparin dodecasaccharide containing double antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2023-06-06 | — | — | CN | claimed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | claimed |
| CN-115417937-A | Heparin decabiose containing double-antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| CN-114957354-A | Heparin pentasaccharide structural compound | 南开大学 | 2022-08-30 | — | — | CN | claimed |
| CN-122080097-A | Fucosylated heparin pentasaccharide and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122080097-A | Fucosylated heparin pentasaccharide and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20220072032-A1 | INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | AARHUS UNIVERSITET (DK) | 2022-03-10 | — | — | US | disclosed |
| CN-114053251-A | Sulfated polysaccharide inhalation preparation and application thereof in preventing and treating new coronavirus related diseases | 苏州融析生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072032-A1 | INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | PCSK9, PCSK6, PCSK7 | SERPINC1 262/4885FGF1 3794/4885F10 3605/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | SERPINC1 18/4885FGF1 1060/4885F10 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.